CSI Market
Sign In | Register

Spark Therapeutics Inc (ONCE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ONCE Annual Cash Flow →
This cash flow overview for Spark Therapeutics Inc spans from Sep 30 2018 to Sep 30 2019, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2019)
9 Months 		(Jun 30 2019) (Mar 31 2019) (Dec 31 2018) (Sep 30 2018)
Operating Activities
Income-185.19
Depreciation & amortization7.54
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-6.22
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets1.63
Share-based Compensation34.55
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Impairment Of Intangible Assets Excluding Goodwill-
Equity Securities Fv Ni Unrealized Gain Loss0.65
Increase Decreasein Deferred Rent Credits-
Increase Decrease In Contract With Customer Liability-5.16
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables19.23
Increase (Decrease) in Accounts Payable and Accrued Liabilities3.67
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets28.06
Other Working Capital1.27
Other Noncash Income (Expense)-0.47
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-100.45
Investing Activities
Capital Expenditures-17.68
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities305.66
Payments to Acquire Marketable Securities-76.02
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities211.96
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.74
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.68
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Convertible Preferred Units-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.06
Effect of exchange rate on cash flow-0.06
Discontinued operations0.00
Free Cash Flow-118.13
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Spark Therapeutics Inc cash flow history.

Sign In Create Free Account

About ONCE Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.